{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:18Z","timestamp":1790352198230,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2022CR53"],"award-info":[{"award-number":["2022CR53"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MedComm"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with B\u2010cell hyperactivity. Telitacicept is a transmembrane activator, calcium modulator, and cyclophilin ligand interactor\u2010Fc fusion protein, which can neutralize both B\u2010cell lymphocyte stimulator and a proliferation\u2010inducing ligand. Patients with active SLE who received telitacicept were prospectively followed at month 1, 3, 6, 9, and 12 after telitacicept initiation. Thirty\u2010seven participants were involved and followed for 6.00 [3.00, 6.00] months. SRI\u20104 rate at month 6 was 44.7%. The median dosage of prednisone was decreased by 43.8% (from 10 to 5.62\u00a0mg\/d) at month 6. The anti\u2010dsDNA level was significantly decreased, while complement levels were significantly increased at month 6 from baseline. Continuously significant reductions in serum immunoglobin (Ig)G IgA, and IgM levels were also observed. Patients experienced significant decreases in the numbers of total and naive B cells, whereas memory B cells and T cell populations did not change. The number of NK cells was significantly increased during the follow\u2010up. At month 6, 58.3% (14 out of 24) patients experienced improved fatigue accessed by FACIT\u2013Fatigue score exceeding the minimum clinically important difference of 4. Most adverse events were mild, but one each case of severe hypogammaglobulinemia, psychosis with suicidal behavior, and B\u2010cell lymphoma were occurred. In our first prospective real\u2010world study, telitacicept treatment led to a significant clinical and laboratory improvement of disease activity, as well as fatigue amelioration in patients with SLE. Safety profile was favorable overall, but more studies are greatly needed.<\/jats:p>","DOI":"10.1002\/mco2.515","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T01:59:28Z","timestamp":1711245568000},"source":"Crossref","is-referenced-by-count":22,"title":["B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single\u2010arm cohort study of telitacicept"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-8882","authenticated-orcid":false,"given":"Lanlan","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology Peking University First Hospital  Beijing China"},{"name":"National Clinical Research Center for Skin and Immune Diseases Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology Peking University First Hospital  Beijing China"},{"name":"National Clinical Research Center for Skin and Immune Diseases Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology Peking University First Hospital  Beijing China"},{"name":"National Clinical Research Center for Skin and Immune Diseases Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerong","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology Peking University First Hospital  Beijing China"},{"name":"National Clinical Research Center for Skin and Immune Diseases Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology Peking University First Hospital  Beijing China"},{"name":"National Clinical Research Center for Skin and Immune Diseases Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Nephrology Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Nephrology Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxue","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology Peking University First Hospital  Beijing China"},{"name":"National Clinical Research Center for Skin and Immune Diseases Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,23]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318789788"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202006020"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529\u20100131(199810)41:10"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281\u2010199909000\u201000005"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.33"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41232\u2010016\u20100015\u20104"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2006.04.006"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2022.58.1.3352743"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.01.002"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001591\u20101"},{"key":"e_1_2_10_14_1","unstructured":"WuD LiJ XuD et\u00a0al.Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b randomised double\u2010blind placebo\u2010controlled trial.Ann Rheum Dis. Published online December 21 2023. doi:10.1136\/ard\u20102023\u2010224854"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(10)61354\u20102"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"e_1_2_10_17_1","unstructured":"Telitacicept a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation\u2010Inducing Ligand (APRIL) in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study. ACR Meeting Abstracts. Accessed May 29 2023.https:\/\/acrabstracts.org\/abstract\/telitacicept\u2010a\u2010human\u2010recombinant\u2010fusion\u2010protein\u2010targeting\u2010b\u2010lymphocyte\u2010stimulator\u2010blys\u2010and\u2010a\u2010proliferation\u2010inducing\u2010ligand\u2010april\u2010in\u2010systemic\u2010lupus\u2010erythematosus\u2010sle\u2010results\u2010of\u2010a\u2010phase\u20103\u2010study\/"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221097812"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221141253"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus\u20102023\u2010001074"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102011\u2010200937"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41253"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.852162"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34400"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067\u2010013\u20102176\u20108"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4RU0315\u2010081RR"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.12.014"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102013\u2010205067"},{"key":"e_1_2_10_29_1","unstructured":"Belimumab (Benlysta\u25bc): increased risk of serious psychiatric events seen in clinical trials. GOV.UK. Accessed July 8 2023.https:\/\/www.gov.uk\/drug\u2010safety\u2010update\/belimumab\u2010benlysta\u2010increased\u2010risk\u2010of\u2010serious\u2010psychiatric\u2010events\u2010seen\u2010in\u2010clinical\u2010trials"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus\u20102021\u2010000534"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1619936"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa120"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067\u2010021\u201005940\u2010z"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac225"},{"issue":"2","key":"e_1_2_10_35_1","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman DD","year":"2002","journal-title":"J Rheumatol"},{"issue":"7","key":"e_1_2_10_36_1","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay EM","year":"1993","journal-title":"Q J Med"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102019\u2010216753"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0885\u20103924(96)00274\u20106"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20101\u201079"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313476360"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23788"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24698"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1191\/096120399680411281"}],"container-title":["MedComm"],"original-title":[],"language":"it","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mco2.515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T16:49:24Z","timestamp":1724172564000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mco2.515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,23]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1002\/mco2.515"],"URL":"https:\/\/doi.org\/10.1002\/mco2.515","archive":["Portico"],"relation":{},"ISSN":["2688-2663","2688-2663"],"issn-type":[{"value":"2688-2663","type":"print"},{"value":"2688-2663","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,23]]},"article-number":"e515"}}